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LETTERS TO THE EDITOR
Drug related toxicity in lung
transplant recipients
(n  =  1)  were  some  of  the  complications  the  authors  would
like  to  report.  No  relationship  was  found  between  the  need
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PDuring  the  last  two  decades,  lung  transplantation  (LTx)  has
become  a  life-saving  intervention  for  patients  presenting
with  end-stage  respiratory  disease.1
The  lung  graft,  in  contrast  to  all  other  transplanted
organs,  is  in  permanent  contact  with  the  external  envi-
ronment  and  is  thus  exposed  to  various  inhaled  agents.
Moreover,  it  contains  a  huge  amount  of  donor  antigen-
presenting  cells  constantly  processing  and  presenting  HLA
alloantigens  to  recipient  lymphocytes  that  initiate  a  process
of  immune  recognition.2 Thus  a  successful  lung  transplant
relies  on  an  appropriate  immunosuppressive  strategy  and
balance.3 In  fact  the  two  main  causes  of  death  after  LTx
are  chronic  rejection  of  the  allograft  and  infections.
Although  advances  have  been  made  and  varied  immuno-
suppressive  protocols  are  being  used,  speciﬁc  drugs,  such  as
calcineurin  inhibitors  and  proliferation  inhibitors  (PIs),  are
very  toxic,  even  at  low  doses.  Nevertheless,  they  are  con-
sidered  to  be  indispensable  in  lung  transplantation.4 Thus,
with  LTx  came  along  drug  toxicity.
We  would  like  to  report  the  results  of  our  own  series.
We  retrospectively  evaluated  patients  with  pulmonary
transplantation  followed  at  our  Centre  since  2005.  The  lung
transplant  was  performed  by  two  different  transplantation
Groups  --  Hospital  de  Santa  Marta  (Lisbon)  and  at  Hospi-
tal  Juan  Canalejo  (Corunha),  according  to  the  Portuguese
Health  System  indications  for  lung  transplant.  After  the
transplant,  although  patients  still  maintained  follow-up  at
the  transplant  centre,  they  were  referred  to  our  Special-
ized  Clinic  for  Lung  Transplanted  patients  which  works  very
closely  with  both  centres.
Thirty-two  patients  were  included,  19  (59.4%)  were  male;
the  mean  age  at  transplant  was  44.9  years.  The  patients
have  been  followed  for  a  mean  time  of  30.78  months  after
LTx.  The  initial  immunosuppressive  protocol  used  in  all
patients  was  the  association  of  steroids,  cyclosporine  and
azathoprine.  Only  six  patients  are  still  with  it,  in  20  patients
it  was  changed  due  to  acute  rejection  and  in  six  patients  due
to  chronic  rejection.
In  14  patients  the  immunosuppressive  therapy  had  to
be  changed,  more  than  once,  due  to  drug  induced  tox-
icity.  Two  patients  had  malignancy  diagnosis  (lymphoma),
gastric  symptoms  were  the  most  frequent  complaint,  renal
malfunction,  hirsutism  (n  =  1),  and  gingival  hyperplasia
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ollow-up.
Among  the  diseases  that  needed  to  be  treated  but  did
ot  require  an  immunosuppressive  therapy  change,  diabetes
n  =  10,  31.5%),  dislipidemia  (n  =  12,  37.5%)  and  arterial
ypertension  (n  =  4,  12.5%)  were  found  to  be  the  most  preva-
ent.
Lung  transplantation  may  be  a  life-saving  intervention
or  end-stage  respiratory  disease.  With  the  growing  num-
er  of  long-term  survivors  of  lung  transplants,  chronic
ejection  and  toxicity  have  emerged  as  major  problems.
rug  induced  toxicity  is  prevalent  and  the  clinicians  car-
ng  for  those  patients  have  to  be  well  aware  of  this  so
hat  it  can  be  diagnosed,  addressed  and  treated  as  early  as
ossible.
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